FEB 2 1 2000 AUGUSTAN



CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mall in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

Fdb. 15, 2001

Debra L. Dennett

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In re Application of:

W. Antoni Kudlicki Matthew M. Winkler

Brittan L. Pasloske

Serial No.: 09/669,301

Filed: September 25, 2000

For: NUCLEASE INHIBITOR COCKTAIL

MAY 3 1 2001

Group Art Unit: 1645

TECH CENTER 1600/2900

Examiner: Unknown

Atty. Dkt. No.: AMBI:052US/DLD

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents Washington, D.C. 20231

Sir:

A corrected filing receipt is hereby requested in view of the error which appears in the original. For the convenience of the Patent and Trademark Office, attached is a photocopy of the original receipt on which the error has been noted in red.

There is an error in Applicants' name. Please delete "MATHEW" and insert -- MATTHEW --.

Because the error is not due to any error by Applicants, no fee is believed to be due in connection with the filing of this document. However, should any fee under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby

authorized to deduct said fee from Fulbright & Jaworski Deposit Account No.: 50-1212/10022802/DLD. In support of the requested correction, Applicants attach hereto a copy of the inventors' Declaration filed January 18, 2001.

FEB 2 1 2001 AU

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Debra L. Dennett Reg. No. 46,370 Attorney for Applicants RECEIVED

MAY 3 1 2001

TECH CENTER 1600/2900

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

February 15, 2001





COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

 APPLICATION NUMBER
 FILING DATE
 GRP ART UNIT
 FIL FEE RECID
 ATTY.DOCKET.NO
 DRAWINGS
 TOT CLAIMS
 IND CLAIMS

 ✓ 09/669.301
 ✓ 09/25/2000
 1645
 1460
 10022802/AMBI:052US
 50
 4

Fulbright & Jaworski LLP 600 Congress Avenue Suite 2400 Austin, TX 78701 MAY 3 1 2001

TECH CENTER 1600/2900

Date Mailed: 02/01/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

W. Antoni Kudlicki, Austin, TX;

MAtthew M. Winkler, Austin, TX;

✓Brittan L. Pasloske, Austin, TX;

Continuing Data as Claimed by Applicant

✓THIS APPLN CLAIMS BENEFIT OF 60/155,874 09/24/1999

Foreign Applications

If Required, Foreign Filing License Granted 11/19/2000

** SMALL ENTITY **

Title

Nuclease inhibitor cocktail

Preliminary Class

435

Data entry by: GENTRY, CHRISTINE

Team: OIPE

Date: 02/01/2001

initials



LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231